Foresite Capital Management VI LLC
CIK 2013341 · View on SEC EDGAR ↗
- Portfolio value
- $642.6M
- Positions
- 23
- As of
- June 30, 2026
#3,232 of 9,443 by 13F value · top 34.2%
Portfolio value QoQ: +39.6% 13F does not disclose cash
- Top 10 holdings weight
- 81.55%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 19
- Effective number of positions
- 8.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 10.91% Est. buys $176,708,925 · sells $60,170,016
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 56.1% still held
- New positions
- 8
- Increased
- 6
- Decreased
- 1
- Closed
- 2
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Sector breakdown
Healthcare
89.1%
Other/Unmapped
10.9%
Full portfolio 23 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| CGON CG Oncology, Inc. - Common stock | $168,358,233 | 26.20% | 2,369,574 | $18,008,873 | Up ×1 | ||
| ALMS Alumis Inc. - Common Stock | $119,529,434 | 18.60% | 4,247,670 | $25,953,264 | |||
| Unknown issuer (CUSIP: 81221K108) | $38,651,196 | 6.02% | 1,779,521 | Up ×1 | |||
| DNLI Denali Therapeutics Inc. - Common Stock | $35,924,950 | 5.59% | 1,396,771 | $12,693,507 | Up ×2 | ||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $32,734,121 | 5.09% | 879,713 | $22,713,361 | Up ×1 | ||
| AGIO Agios Pharmaceuticals, Inc. - Common Stock | $29,131,350 | 4.53% | 785,000 | $11,370,600 | Up ×1 | ||
| CRVS Corvus Pharmaceuticals, Inc. - Common Stock | $27,358,621 | 4.26% | 1,831,233 | $567,682 | |||
| Unknown issuer (CUSIP: 698955101) | $27,343,834 | 4.26% | 999,044 | Up ×1 | |||
| GHRS GH Research PLC - Ordinary Shares | $25,280,452 | 3.93% | 940,493 | $20,844,634 | Up ×1 | ||
| JBIO Jade Biosciences, Inc. - Common Stock | $19,701,741 | 3.07% | 886,667 | $15,205,741 | Up ×1 | ||
| HNGE Hinge Health, Inc. Class A Common Stock | $18,293,200 | 2.85% | 220,400 | $9,794,576 | |||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $16,779,890 | 2.61% | 146,332 | $4,591,898 | |||
| ATAI AtaiBeckley Inc. - Common Stock | $14,492,500 | 2.26% | 2,750,000 | $4,757,500 | |||
| VSTM Verastem, Inc. - Common Stock | $12,020,130 | 1.87% | 3,146,631 | $-4,657,014 | |||
| BEAM Beam Therapeutics Inc. - Common Stock | $11,325,600 | 1.76% | 330,000 | Up ×1 | |||
| NERV Minerva Neurosciences, Inc - Common Stock | $11,019,991 | 1.71% | 1,985,584 | $-949,274 | Down ×1 | ||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $10,468,586 | 1.63% | 301,341 | Up ×1 | |||
| AURA Aura Biosciences, Inc. - Common Stock | $9,466,671 | 1.47% | 1,333,334 | Up ×1 | |||
| CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $7,933,414 | 1.23% | 212,010 | $233,211 | |||
| Unknown issuer (CUSIP: G75226103) | $3,210,000 | 0.50% | 300,000 | Up ×1 | |||
| ZURA Zura Bio Limited - Class A Ordinary shares | $2,655,000 | 0.41% | 450,000 | $-22,500 | |||
| Unknown issuer (CUSIP: 482931102) | $826,125 | 0.13% | 37,500 | Up ×1 | |||
| IRON Disc Medicine, Inc. - Common Stock | $70,946 | 0.01% | 970 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 81221K108) | $38,651,196 | 1,779,521 | 6.02% |
| Unknown issuer (CUSIP: 698955101) | $27,343,834 | 999,044 | 4.26% |
| BEAM | $11,325,600 | 330,000 | 1.76% |
| AVBP | $10,468,586 | 301,341 | 1.63% |
| AURA | $9,466,671 | 1,333,334 | 1.47% |
| Unknown issuer (CUSIP: G75226103) | $3,210,000 | 300,000 | 0.50% |
| Unknown issuer (CUSIP: 482931102) | $826,125 | 37,500 | 0.13% |
| IRON | $70,946 | 970 | 0.01% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| ALMS | Price move only | +0 | +$26.0M |
| CLDX | Bought more | +564K | +$22.7M |
| CGON | Bought more | +148K | +$18.0M |
| JBIO | Bought more | +567K | +$15.2M |
| DNLI | Bought more | +187K | +$12.7M |
| AGIO | Bought more | +260K | +$11.4M |
| HNGE | Price move only | +0 | +$9.8M |
| ATAI | Price move only | +0 | +$4.8M |
| VSTM | Price move only | +0 | -$4.7M |
| KYMR | Price move only | +0 | +$4.6M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| CNTA | June 30, 2026 | 1,364,019 | $54,178,835 | No longer tracked |
| RAPT | March 31, 2026 | 1,562,500 | $52,921,875 | No longer tracked |
| NTRA | March 31, 2026 | 67,356 | $15,430,586 | 62.6% |
| AKRO | Dec. 31, 2025 | 244,900 | $11,627,852 | No longer tracked |
| BCAX | Sept. 30, 2025 | 949,260 | $8,818,625 | 55.2% |
| EWTX | Sept. 30, 2025 | 585,000 | $7,669,350 | 170.6% |
| OKUR | June 30, 2026 | 1,445,783 | $5,985,542 | -12.9% |
| XENE | Sept. 30, 2025 | 160,000 | $5,008,000 | 49.9% |
| CGEM | Sept. 30, 2025 | 594,025 | $4,473,008 | 266.9% |
| GPCR | Sept. 30, 2025 | 210,000 | $4,355,400 | 81.6% |
| ALLO | Sept. 30, 2025 | 2,875,357 | $3,249,153 | 70.6% |
| IDYA | Sept. 30, 2025 | 144,468 | $3,036,717 | 49.0% |
| RNA | Dec. 31, 2025 | 40,000 | $1,742,800 | -81.8% |
| CASIF | Dec. 31, 2025 | 979,956 | $1,626,727 | No longer tracked |
| SYRE | Sept. 30, 2025 | 70,000 | $1,047,900 | 551.4% |
| VRDN | Sept. 30, 2025 | 1,974 | $27,597 | 14.1% |